Continuous Improvement

Good morning folks,

So we talked about Bios being important for the the markets in this weeks video and things were looking pretty good on Saturday for the sector. Then we received more data out of the ASH conference on Sunday that put a damper on some of the recent high fliers like BLUE which was in this weeks stocks to watch video. BLUE is taking a 30 percent haircut premarket. THLD is another BIO getting crushed down 69 percent as I write this. Those two stocks may not take down the whole bio sector but they will likely make it more challenging for the IBB to break over resistance. There is a tremendous amount of data being released withing the sector and there are likely to be a couple of winners as well. 

Oil is looking like it could test those lows and the dollar is gaining strength this morning premarket. We could have a bit of a choppy day once again. 

Market Wrap 

http://www.screencast.com/t/1HCmBfMo3u

Stocks to watch 

http://www.screencast.com/t/nYEJ6rdOqo

Stocks on my radar premarket

Bullish and may have a swing or lottos in play

Cautiously optimistic

Very Cautious may even present a short opportunity ..

09:17:28am12/06/15 AFMD	+ Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASH
07:56:09am12/04/15 AFMD	+ Wells Fargo Initiates Coverage on Affimed at Outperform

Active premarklet very tiny float decent cash position potential 8 dolla holla looking for potential day trade setup 

08:03:49am12/07/15 ZGNX

+ Zogenix Reports New Efficacy, Safety Data on ZX008 for Seizure Treatment in Dravet Syndrome

Decent short position decent cash position another potential day trade opportunity potential 16 dolla holla 

• 7:31 am Arrowhead presents data showing that in chronically HBV-infected chimpanzees treated with ARC-520 in combination with nucleoside analogs, 78% exhibited signs of immune reactivationBriefing.com (Mon 7:31AM EST)

Good cash position 25 percent short fairly small float looking for a continuation on the 6 roll

• 1:11 am CTI BioPharma reports Phase 3 results treatment with Pacritinib support the effectiveness of pacritinib across intermediate or high-risk myelofibrosis patient subgroups analyzedBriefing.com (Mon 1:11AM EST)
• Recent equity offering could get some follow through has a tendency to pop and Flop 
• 
  

08:30:39am12/07/15 MEIP

+ MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study

Small floater gapping premarket potential 2 dolla roll